Home PI3K/Akt/mTOR PI3K inhibitor AZD6482 For research use only.

AZD6482

Synonyms: KIN-193

AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

AZD6482 Chemical Structure

AZD6482 Chemical Structure

CAS No. 1173900-33-8

Purity & Quality Control

AZD6482 Related Products

Signaling Pathway

PI3K Signaling Pathways

PI3K Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human RXF393 cell Growth inhibition assay Inhibition of human RXF393 cell growth in a cell viability assay, IC50=0.01154 μM SANGER
human SW982 cell Growth inhibition assay Inhibition of human SW982 cell growth in a cell viability assay, IC50=0.03584 μM SANGER
human MAD-MB-468 cells Function assay Inhibition of PI3Kbeta in human MAD-MB-468 cells assessed as inhibition of Ser473 Akt phosphorylation by cellular potency assay, IC50=0.04 μM 24992874
human KURAMOCHI cell Growth inhibition assay Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50=0.1051 μM SANGER
human A498 cell Growth inhibition assay Inhibition of human A498 cell growth in a cell viability assay, IC50=0.11795 μM SANGER
human YT cell Growth inhibition assay Inhibition of human YT cell growth in a cell viability assay, IC50=0.12066 μM SANGER
human VMRC-RCZ cell Growth inhibition assay Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50=0.14898 μM SANGER
human MDA-MB-415 cell Growth inhibition assay Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50=0.16732 μM SANGER
human J82 cell Growth inhibition assay Inhibition of human J82 cell growth in a cell viability assay, IC50=0.47779 μM SANGER
human SW1710 cell Growth inhibition assay Inhibition of human SW1710 cell growth in a cell viability assay, IC50=0.5292 μM SANGER
human T47D cell Growth inhibition assay Inhibition of human T47D cell growth in a cell viability assay, IC50=0.5327 μM SANGER
human SU-DHL-1 cell Growth inhibition assay Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=0.56813 μM SANGER
human BT-20 cell Growth inhibition assay Inhibition of human BT-20 cell growth in a cell viability assay, IC50=0.59222 μM SANGER
human OS-RC-2 cell Growth inhibition assay Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=0.62388 μM SANGER
human RPMI-6666 cell Growth inhibition assay Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=0.64379 μM SANGER
human OVCAR-3 cell Growth inhibition assay Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=0.67946 μM SANGER
human NALM-6 cell Growth inhibition assay Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=0.70465 μM SANGER
human RS4-11 cell Growth inhibition assay Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=0.73806 μM SANGER
human SK-MES-1 cell Growth inhibition assay Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50=0.78967 μM SANGER
human ES7 cell Growth inhibition assay Inhibition of human ES7 cell growth in a cell viability assay, IC50=0.81286 μM SANGER
human NCI-H2342 cell Growth inhibition assay Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=0.84294 μM SANGER
human SCC-9 cell Growth inhibition assay Inhibition of human SCC-9 cell growth in a cell viability assay, IC50=0.8577 μM SANGER
human EW-7 cell Growth inhibition assay Inhibition of human EW-7 cell growth in a cell viability assay, IC50=0.86356 μM SANGER
human HH cell Growth inhibition assay Inhibition of human HH cell growth in a cell viability assay, IC50=0.96222 μM SANGER
human A427 cell Growth inhibition assay Inhibition of human A427 cell growth in a cell viability assay, IC50=0.99505 μM SANGER
human Daudi cell Growth inhibition assay Inhibition of human Daudi cell growth in a cell viability assay, IC50=1.06888 μM SANGER
human P30-OHK cell Growth inhibition assay Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=1.07138 μM SANGER
human HGC-27 cell Growth inhibition assay Inhibition of human HGC-27 cell growth in a cell viability assay， IC50=1.1816 μM SANGER
human CAMA-1 cell Growth inhibition assay Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=1.2001 μM SANGER
human SK-OV-3 cell Growth inhibition assay Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=1.20444 μM SANGER
human NCI-H1048 cell Growth inhibition assay Inhibition of human NCI-H1048 cell growth in a cell viability assay, IC50=1.22579 μM SANGER
human MEL-HO cell Growth inhibition assay Inhibition of human MEL-HO cell growth in a cell viability assay, IC50=1.24238 μM SANGER
human NKM-1 cell Growth inhibition assay Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=1.28636 μM SANGER
human NCI-H650 cel Growth inhibition assay Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50=1.30076 μM SANGER
human HAL-01 cell Growth inhibition assay Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=1.30175 μM SANGER
human 786-0 cell Growth inhibition assay Inhibition of human 786-0 cell growth in a cell viability assay, IC50=1.31283 μM SANGER
human GI-1 cell Growth inhibition assay Inhibition of human GI-1 cell growth in a cell viability assay, IC50=1.31808 μM SANGER
human Becker cell Growth inhibition assay Inhibition of human Becker cell growth in a cell viability assay, IC50=1.36315 μM SANGER
human CCF-STTG1 cell Growth inhibition assay Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=1.42525 μM SANGER
human MC116 cell Growth inhibition assay Inhibition of human MC116 cell growth in a cell viability assay, IC50=1.46122 μM SANGER
human MDA-MB-468 cell Growth inhibition assay Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50=1.53736 μM SANGER
human NB12 cell Growth inhibition assay Inhibition of human NB12 cell growth in a cell viability assay, IC50=1.54842 μM SANGER
human LXF-289 cell Growth inhibition assay Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=1.55104 μM SANGER
human MFE-296 cell Growth inhibition assay Inhibition of human MFE-296 cell growth in a cell viability assay, IC50=1.56836 μM SANGER
human SNU-423 cell Growth inhibition assay Inhibition of human SNU-423 cell growth in a cell viability assay, IC50=1.57192 μM SANGER
human NCI-H2291 cell Growth inhibition assay Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50=1.5761 μM SANGER
human OCUB-M cell Growth inhibition assay Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=1.58314 μM SANGER
human KU812 cell Growth inhibition assay Inhibition of human KU812 cell growth in a cell viability assay, IC50=1.59628 μM SANGER
human HuO9 cell Growth inhibition assay Inhibition of human HuO9 cell growth in a cell viability assay, IC50=1.6128 μM SANGER
human 639-V cell Growth inhibition assay Inhibition of human 639-V cell growth in a cell viability assay, IC50=1.63144 μM SANGER
human HCC70 cell Growth inhibition assay Inhibition of human HCC70 cell growth in a cell viability assay, IC50=1.66146 μM SANGER
human SNB75 cell Growth inhibition assay Inhibition of human SNB75 cell growth in a cell viability assay, IC50=1.66508 μM SANGER
human D-336MG cell Growth inhibition assay Inhibition of human D-336MG cell growth in a cell viability assay, IC50=1.6688 μM SANGER
human LoVo cell Growth inhibition assay Inhibition of human LoVo cell growth in a cell viability assay, IC50=1.73825 μM SANGER
human EB2 cell Growth inhibition assay Inhibition of human EB2 cell growth in a cell viability assay, IC50=1.75019 μM SANGER
human HSC-2 cell Growth inhibition assay Inhibition of human HSC-2 cell growth in a cell viability assay, IC50=1.75727 μM SANGER
human D-542MG cell Growth inhibition assay Inhibition of human D-542MG cell growth in a cell viability assay, IC50=1.85077 μM SANGER
human COLO-684 cell Growth inhibition assay Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=2.20032 μM SANGER
human GDM-1 cell Growth inhibition assay Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=2.24206 μM SANGER
human SW1088 cell Growth inhibition assay Inhibition of human SW1088 cell growth in a cell viability assay, IC50=2.48143 μM SANGER
human SF295 cell Growth inhibition assay Inhibition of human SF295 cell growth in a cell viability assay, IC50=2.76955 μM SANGER
human NCI-H2030 cell Growth inhibition assay Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50=2.90288 μM SANGER
human NCI-H1755 cell Growth inhibition assay Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50=3.27063 μM SANGER
human MDA-MB-361 cell Growth inhibition assay Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=3.52709 μM SANGER
Click to View More Cell Line Experimental Data

Biological Activity

Description AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.
Targets
PI3Kβ [1]
(Cell-free assay)		 PI3Kδ [1]
(Cell-free assay)		 DNA-PK [1]
(Cell-free assay)		 PI3Kα [1]
(Cell-free assay)
10 nM 80 nM 420 nM 870 nM
In vitro
In vitro AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]
Kinase Assay Assay of PI3K enzyme inhibition
The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
Cell Research Cell lines Human platelet pellet
Concentrations 0–60 nM, dissolved in DMSO
Incubation Time 5 min
Method For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 1015/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.

Chemical Information & Solubility

Molecular Weight 408.45 Formula

C22H24N4O4
CAS No. 1173900-33-8 SDF Download AZD6482 SDF
Smiles CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 82 mg/mL ( (200.75 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy AZD6482 | AZD6482 supplier | purchase AZD6482 | AZD6482 cost | AZD6482 manufacturer | order AZD6482 | AZD6482 distributor